Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice

Molecular Immunology

Volumn 47, Issue 1, 2009, Pages 87-95

  Durova, Oxana M ^a   Vorobiev, Ivan I ^a   Smirnov, Ivan V ^a   Reshetnyak, Andrew V ^b   Telegin, Georgy B ^a   Shamborant, Olga G ^a   Orlova, Nadezda A ^a   Genkin, Dmitry D ^c   Bacon, Andrew ^c   Ponomarenko, Natalia A ^a   Friboulet, Alain ^d   Gabibov, Alexander G ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b YALE UNIVERSITY   (United States)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

^d UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Autoimmunity; Catalytic antibodies; EAE; HIV 1 DNA protein vaccine; Liposome delivery; SJL mice

Indexed keywords

CATALYTIC ANTIBODY; COAT PROTEIN; DNA VACCINE; EPITOPE; GLYCOPROTEIN GP 120; LIPOSOME; MONOCLONAL ANTIBODY; MYELIN BASIC PROTEIN; PEPTIDYLPHOSPHONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CATALYSIS; CONTROLLED STUDY; ENCAPSULATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; PURIFICATION; VACCINATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, CATALYTIC; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; CAPSID PROTEINS; EPITOPES; HIV ENVELOPE PROTEIN GP120; IMMUNIZATION; MICE; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 70350757719     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.12.020     Document Type: Article

References (50)

1. Bone R., Sampson N.S., Bartlett P.A., and Agard D.A. Crystal structures of alpha-lytic protease complexes with irreversibly bound phosphonate esters. Biochemistry 30 (1991) 2263-2272
2. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., Bouma P., Cham F., Choudhary A., Rybak S.M., Fouts T., Montefiori D.C., Broder C.C., Quinnan Jr. G.V., and Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363 (2007) 79-90
3. Friboulet A., Avalle B., Débat H., and Thomas D. A possible role of catalytic antibodies in metabolism. Immunol. Today 20 (1999) 474-475
4. Gabibov A.G., Friboulet A., Thomas D., Demin A.V., Ponomarenko N.A., Vorobiev I.I., Pillet D., Paon M., Alexandrova E.S., Telegin G.B., Reshetnyak A.V., Grigorieva O.V., Gnuchev N.V., Malishkin K.A., and Genkin D.D. Antibody proteases: induction of catalytic response. Biochemistry (Mosc) 67 (2002) 1168-1179
5. Gach J.S., Quendler H., Ferko B., Katinger H., and Kunert R. Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine. Mol. Biotechnol. 39 (2008) 119-125
6. Gorny M.K., Stamatatos L., Volsky B., Revesz K., Williams C., Wang X.H., Cohen S., Staudinger R., and Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79 (2005) 5232-5237
7. Gregoriadis G., Andrew Bacon A., McCormack B., and Laing P. In: Torchilin V.P. (Ed). "Genetic Vaccines: A Role for Liposomes" in Nanoparticulates as Drug Carriers (2006), Imperial College Press Chapter 4, pp. 43-53
8. Greenland J.R., and Letvin N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25 (2007) 3731-3741
9. He Y., Honnen W.J., Krachmarov C.P., Burkhart M., Kayman S.C., Corvalan J., and Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 169 (2002) 595-605
10. Hilvert D. Critical analysis of antibody catalysis. Annu. Rev. Biochem. 69 (2000) 751-793
11. Honnen W.J., Krachmarov C., Kayman S.C., Gorny M.K., Zolla-Pazner S., and Pinter A. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81 (2007) 1424-1432
12. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev. Vaccines 5 (2006) 803-825
13. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
14. Kolesnikov A.V., Kozyr A.V., Alexandrova E.S., Koralewski F., Demin A.V., Titov M.I., Avalle B., Tramontano A., Paul S., Thomas D., Gabibov A.G., and Friboulet A. Enzyme mimicry by the antiidiotypic antibody approach. Proc. Natl. Acad. Sci. USA 97 (2000) 13526-13531
15. Krishnan R., Zhang E., Hakansson K., Arni R.K., Tulinsky A., Lim-Wilby M.S., Levy O.E., Semple J.E., and Brunck T.K. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry 37 (1998) 12094-12103
16. Lacroix-Desmazes S., Moreau A., Sooryanarayana, Bonnemain C., Stieltjes N., Pashov A., Sultan Y., Hoebeke J., Kazatchkine M.D., and Kaveri S.V. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat. Med. 5 (1999) 1044-1047
17. Lacroix-Desmazes S., Bayry J., Kaveri S.V., Hayon-Sonsino D., Thorenoor N., Charpentier J., Luyt C.E., Mira J.P., Nagaraja V., Kazatchkine M.D., Dhainaut J.F., and Mallet V.O. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. USA 102 (2005) 4109-4113
18. Lerner R.A., Benkovic S.J., and Schultz P.G. At the crossroads of chemistry and immunology: catalytic antibodies. Science 252 (1991) 659-667
19. Lerner R.A., and Barbas C.F. Using the process of reactive immunization to induce catalytic antibodies with complex mechanisms: aldolases. Acta Chem. Scand. 50 (1996) 672-678
20. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin. Immunopathol. 28 (2006) 255-265
21. Miller D., and Karpus W.J. In: Coligan J.E. (Ed). Current Protocols in Immunology (1996), Wiley, New York
22. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. (2005) Chapter 12: Unit 12 11
23. Nardi M., Tomlinson S., Greco M.A., and Karpathin S. Complement-independent peroxide induced antibody lysis of platelets in HIV-1 related immune thrombocytopenia. Cell 106 (2001) 551-561
24. Paul S., Volle D.J., Beach C.M., Johnson D.R., Powell M.J., and Massey R.J. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244 (1989) 1158-1162
25. Paul S., Li L., Kalaga R., Wilkins-Stevens P., Stevens F.J., and Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270 (1995) 15257-15261
26. Paul S., Karle S., Planque S., Taguchi H., Salas M., Nishiyama Y., Handy B., Hunter R., Edmundson A., and Hanson C. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J. Biol. Chem. 279 (2004) 39611-39619
27. Pettinelli C.B., and McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2-T lymphocytes. J. Immunol. 127 (1981) 1420-1423
28. Pietersz G.A., Tang C.K., and Apostolopoulos V. Structure and design of polycationic carriers for gene delivery. Mini Rev. Med. Chem. 6 (2006) 1285-1298
29. Planque S., Nishiyama Y., Taguchi H., Salas M., Hanson C., and Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun. Rev. 7 (2008) 473-479
30. Pollard S.R., Meier W., Chow P., Rosa J.J., and Wiley D.C. CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 defined by proteolytic digestion. Proc. Natl. Acad. Sci. USA 88 (1991) 11320-11324
31. Ponomarenko N.A., Durova O.M., Vorobiev I.I., Aleksandrova E.S., Telegin G.B., Chamborant O.G., Sidorik L.L., Suchkov S.V., Alekberova Z.S., Gnuchev N.V., and Gabibov A.G. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J. Immunol. Methods 269 (2002) 197-211
32. Ponomarenko N.A., Durova O.M., Vorobiev I.I., Belogurov Jr. A.A., Kurkova I.N., Petrenko A.G., Telegin G.B., Suchkov S.V., Kiselev S.L., Lagarkova M.A., Govorun V.M., Serebryakova M.V., Avalle B., Tornatore P., Karavanov A., Morse H.C., Thomas D., Friboulet A., and Gabibov A.G. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc. Natl. Acad. Sci. USA 103 (2006) 281-286
33. Ponomarenko N.A., Vorobiev I.I., Alexandrova E.S., Reshetnyak A.V., Telegin G.B., Khaidukov S.V., Avalle B., Karavanov A., Morse H.C., Thomas D., Friboulet A., and Gabibov A.G. Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry 45 (2006) 324-330
34. Ponomarenko N.A., Pillet D., Paon M., Vorobiev I.I., Smirnov I.V., Adenier H., Avalle B., Kolesnikov A.V., Kozyr A.V., Thomas D., Gabibov A.G., and Friboulet A. Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry 46 (2007) 14598-14609
35. Reshetnyak A.V., Armentano M.F., Ponomarenko N.A., Vizzuso D., Durova O.M., Ziganshin R., Serebryakova M., Govorun V., Gololobov G., Morse H.C., Friboulet A., Makker S.P., Gabibov A.G., and Tramontano A. Routes to covalent catalysis by reactive selection for nascent protein nucleophiles. J. Am. Chem. Soc. 129 (2007) 16175-16182
36. Robinson H.L. HIV/AIDS vaccines: 2007. Clin. Pharmacol. Ther. 82 (2007) 686-693
37. Sakai K., Zamvil S.S., Mitchell D.J., Lim M., Rothbard J.B., and Steinman L. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J. Neuroimmunol. 19 (1988) 21-32
38. Shioda T., Oka S., Xin X., Liu H., Harukuni R., Kurotani A., Fukushima M., Hasan M.K., Shiino T., Takebe Y., Iwamoto A., and Nagai Y. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J. Virol. 71 (1997) 4871-4881
39. Shuster A.M., Gololobov G.V., Kvashuk O.A., Bogomolova A.E., Smirnov I.V., and Gabibov A.G. DNA hydrolyzing autoantibodies. Science 256 (1992) 665-667
40. Tan L.J., Kennedy M.K., and Miller S.D. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J. Immunol. 148 (1992) 2748-2755
41. Tawfik D.S., Chap R., Green B.S., Sela M., and Eshhar Z. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity?. Proc Natl. Acad. Sci. USA 92 (1995) 2145-2149
42. Voss Jr. E.W., Workman C.J., and Mummert M.E. Detection of protease activity using fluorescence-enhancement globular substrate. Biotechniques 20 (1996) 286-291
43. Walker B.D., and Burton D.R. Toward an AIDS vaccine. Science 320 (2008) 760-764
44. WHO, 2008. World Health Statistic.
45. Wirsching P., Ashley J.A., Lo C.H., Janda K.D., and Lerner R.A. Reactive immunization. Science 270 (1995) 1775-1782
46. Wootla B., Dasgupta S., Dimitrov J.D., Bayry J., Lévesque H., Borg J.Y., Borel-Derlon A., Rao D.N., Friboulet A., Kaveri S.V., and Lacroix-Desmazes S. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J. Immunol. 180 (2008) 7714-7720
47. Wootla B., Nicoletti A., Patey N., Dimitrov J.D., Legendre C., Christophe O.D., Friboulet A., Kaveri S.V., Lacroix-Desmazes S., and Thaunat O. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J. Immunol. 180 (2008) 8455-8460
48. Xu Y., Hixon M.S., Yamamoto N., McAllister L.A., Wentworth A.D., Wentworth P., and Janda K.D. Antibody-catalyzed anaerobic destruction of methamphetamine. Proc. Natl. Acad. Sci. USA 104 (2007) 3681-3686
49. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., and Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007) 732-737
50. Zwick M.B., Kelleher R., Jensen R., Labrijn A.F., Wang M., Quinnan Jr. G.V., Parren P.W., and Burton D.R. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J. Virol. 77 (2003) 6965-6978